- Sotagliflozin Reduces HF Events in T2DM Regardless of Baseline Characteristics, Including HF, CKD and LVEFZhao, Li-Min; Ding, Liang-Liang; Zhan, Ze-Lin; Qiu, Mei*Cardiovascular Drugs and Therapy, 2021, 35(5): 1077-1078.被引 2
- Do four SGLT2 inhibitors lead to different cardiorenal benefits in type 2 diabetes, in chronic heart failure, and in chronic kidney disease?Qiu, Mei*; Ding, Liang-Liang; Zhan, Ze-Lin; Zhou, Hai-RongEuropean Journal of Internal Medicine, 2021, 87: 98-99.被引 3
- The effects of dapagliflozin on kidney and cardiovascular outcomes in patients with chronic kidney disease with and without heart failureHeerspink, J. L.; Wheeler, D. C.; Vart, P.; Jongs, N.; Hou, F. F.; Langkilde, A. M.; Correa-Rotter, R.; Rossing, P.; Sjostrom, C. D.; Toto, R. D.; Chertow, G. M.; Stefansson, B. V.; McMurray, J. J. V.
期刊论文
Meta-analysis of the effects of four factors on the efficacy of SGLT2 inhibitors in patients with HFrEF
2被引7阅读
